buthionine sulfoximine has been researched along with arsenic trioxide in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 24 (68.57) | 29.6817 |
| 2010's | 9 (25.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JC; Chen, YC; Kuo, ML; Yang, CH | 1 |
| Cai, X; Chen, G; Shen, Y | 1 |
| Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y | 1 |
| Cai, X; Huang, X; Zhou, Y | 1 |
| Akao, Y; Kito, M; Nozawa, Y; Ohishi, N; Yagi, K | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lu, SH; Pu, YS | 2 |
| Côté, S; Davison, K; Mader, S; Miller, WH | 1 |
| Aller, P; Amrán, D; de Blas, E; Fernández, C; Ramos, AM; Sancho, P | 1 |
| Hori, S; Kakehi, Y; Kakizuka, A; Maeda, H; Ogawa, O; Ohizumi, H; Segawa, T | 1 |
| Kakehi, Y; Ogawa, O; Wu, XX | 1 |
| Antony, S; Fu, H; Kohlhagen, G; Liao, Z; Liu, H; Pommier, Y; Sordet, O; Stevens, EV | 1 |
| Fung, Y; Lin, B; Liu, D; Ma, X; Qin, J; Wang, W; Ye, N; Yu, L | 1 |
| Engel, RH; Evens, AM | 1 |
| Chow, J; Huang, M; Lee, C; Lin, C; Lin, Y; Liu, C; Liu, HE | 1 |
| Chan, R; Chen, D; Jing, Y; Waxman, S | 1 |
| Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B | 1 |
| Czyz, M; Duechler, M; Stańczyk, M; Stepnik, M | 1 |
| Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP | 2 |
| Han, YH; Kim, SH; Kim, SZ; Park, WH | 2 |
| Kneifel, C; Lösler, S; Rojewski, MT; Schlief, S; Schrezenmeier, H; Thiel, E | 1 |
| Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L | 1 |
| Biswas, S; Byrd, JC; Jarjoura, D; Mo, X; Mone, AP; Muthusamy, N; Vargo, M; Zhao, X | 1 |
| Chan, SY; Ho, PC; Ong, PS | 1 |
| Castellani, P; Ciriolo, MR; Delfino, L; Lucibello, M; Rubartelli, A; Venè, R | 1 |
| Park, WH; You, BR | 1 |
| Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V | 1 |
| Fujii, Y; Komatsu, T; Shigemi, H; Tanaka, Y; Yamauchi, T | 1 |
| Gülden, M; Klauser, E; Maser, E; Seibert, H; Seibert, S | 1 |
| Bhattacharya, S; Chakraborty, A; Chattopadhyay, A; Srivastava, R | 1 |
| Chen, C; Gu, S; Jiang, X; Zhang, Z | 1 |
| Chou, YT; Pu, YS; Wang, AS | 1 |
| Chew, EH; Holmgren, A; Lu, J | 1 |
1 review(s) available for buthionine sulfoximine and arsenic trioxide
| Article | Year |
|---|---|
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Dose-Response Relationship, Drug; Glutathione; Hexanones; Humans; Metalloporphyrins; Models, Biological; Models, Chemical; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species | 2006 |
34 other study(ies) available for buthionine sulfoximine and arsenic trioxide
| Article | Year |
|---|---|
Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Oxides; Tumor Cells, Cultured | 1999 |
[Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Glutathione; Humans; Leukemia; Lymphoma; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Caspases; Cell Division; Cell Nucleus; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Humans; Kinetics; Liver Neoplasms; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Caspase 3; Caspases; Cisplatin; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; G1 Phase; Humans; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Cytotoxicity of arsenic trioxide to transitional carcinoma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Humans; Oxides; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Glutathione; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2003 |
12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cadmium Chloride; Caspase 3; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Immunoblotting; Mitogen-Activated Protein Kinases; Monocytes; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase C; Tetradecanoylphorbol Acetate; Time Factors; U937 Cells | 2004 |
Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glutathione; HeLa Cells; Humans; Hydrogen Peroxide; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Oxides; Prostatic Neoplasms; Reactive Oxygen Species; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Renal Cell; Caspases; Cell Division; Doxorubicin; Drug Synergism; Fluorouracil; Glutathione; Glutathione Transferase; Humans; Kidney Neoplasms; Oxidation-Reduction; Oxides; Tumor Cells, Cultured; Vinblastine | 2004 |
Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Caspases; DNA; DNA Fragmentation; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Gene Expression; Gene Silencing; Humans; Leukemia; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Recombinant Proteins; Tumor Cells, Cultured | 2004 |
Simultaneous and ultrarapid determination of reactive oxygen species and reduced glutathione in apoptotic leukemia cells by microchip electrophoresis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Electrophoresis, Microchip; Fluorescent Dyes; Glutathione; Humans; Lasers; Leukemia, Promyelocytic, Acute; Miniaturization; Oxides; Reactive Oxygen Species; Reproducibility of Results; Rhodamines; Signal Transduction; Spectrometry, Fluorescence; Tumor Cells, Cultured | 2005 |
Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Topics: Acute Disease; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Cell Count; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Drug Resistance, Neoplasm; Glutathione; Humans; Injections, Intraperitoneal; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Oxides; Stromal Cells; Treatment Failure | 2006 |
Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors.
Topics: Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Glutathione; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; Lymphoma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Time Factors; U937 Cells | 2006 |
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines | 2007 |
Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Flow Cytometry; Glutamate-Cysteine Ligase; Glutathione; Humans; Leukemia; Mice; Microscopy, Fluorescence; NF-kappa B; Oxides; Reactive Oxygen Species; Sesquiterpenes | 2008 |
[The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Glutathione; Humans; K562 Cells; Oxides | 2007 |
Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Survival; Ditiocarb; Glutathione; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species; Superoxides | 2008 |
Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Cycle; Cell Membrane; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2008 |
[Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; K562 Cells; Oxides | 2008 |
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Topics: Antimony; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Oxides | 2009 |
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides | 2009 |
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
Topics: Amino Acid Chloromethyl Ketones; Amitrole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Ascorbic Acid; B-Lymphocytes; Buthionine Sulfoximine; Catalase; Cell Line, Tumor; Cysteine Proteases; Cysteine Proteinase Inhibitors; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Activation; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Oxidants; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fibroblasts; Glutathione; Glutathione Peroxidase; Humans; Intracellular Space; Ovarian Neoplasms; Oxidative Stress; Oxides | 2011 |
The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
Topics: Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Cell Survival; Cysteine; Cystine; Glutathione; Glycine; HMGB1 Protein; Humans; Immunohistochemistry; Melanoma; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured | 2011 |
Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Fibroblasts; Glutathione; Humans; Lung; Oxides; Reactive Oxygen Species; Transfection | 2012 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide | 2009 |
BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Buthionine Sulfoximine; Drug Combinations; Gene Knockdown Techniques; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Oxidative Stress; Oxides; Phosphorylation; Proto-Oncogene Proteins | 2014 |
Additivity, antagonism, and synergy in arsenic trioxide-induced growth inhibition of C6 glioma cells: effects of genistein, quercetin and buthionine-sulfoximine.
Topics: Animals; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Genistein; Glioma; Oxides; Quercetin; Rats | 2014 |
Differential in vivo genotoxicity of arsenic trioxide in glutathione depleted mouse bone marrow cells: expressions of Nrf2/Keap1/P62.
Topics: Acetylcysteine; Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Chromatids; Chromosome Aberrations; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Kelch-Like ECH-Associated Protein 1; Male; Membrane Glycoproteins; Mice; Mutagens; Neoplasm Proteins; NF-E2-Related Factor 2; Nuclear Pore Complex Proteins; Oxides | 2015 |
[Study on the resveratrol and arsenic trioxide combination induced apoptosis and its mechanism on lung adenocarcinoma cells].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Drug Synergism; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oxidation-Reduction; Oxides; Resveratrol; Stilbenes; Tumor Cells, Cultured | 2016 |
Antagonistic effect of N-ethylmaleimide on arsenic-mediated oxidative stress-induced poly(ADP-ribosyl)ation and cytotoxicity.
Topics: Antidotes; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Comet Assay; DNA Damage; DNA Repair; Ethylmaleimide; Humans; Oxidative Stress; Oxides; Poly ADP Ribosylation | 2017 |
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Topics: Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Glutathione; Humans; Molecular Sequence Data; Neoplasms; Oxidation-Reduction; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thioredoxin-Disulfide Reductase | 2007 |